Big Changes in AML Care as Targeted Therapy Options Expand
About this episode
Dr. Amir Fathi discusses the expanding treatment options for acute myeloid leukemia with Dr. Robert A. Figlin.
Options for the treatment of acute myeloid leukemia (AML) are rapidly expanding, says Amir Fathi, MD, associate professor of medicine at Harvard Medical School in Boston and program director of the Center for Leukemia at Massachusetts General Hospital. “Over the course of the last 10 to 12 years, there have been a series of approvals, predominantly for targeted therapies,” he explains. Speaking with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, Dr. Fathi outlines how and when to look for mutations in AML and key considerations for various targeted therapies. He also shares what developments he is anticipating. “I’m most excited about where we’re moving in the upfront setting.” Dr. Fathi reported various financial relationships. Dr. Figlin reported various financial relationships.
People in this episode
Host: Robert A. Figlin, MD
Guest: Amir Fathi, MD
Topics covered
- acute myeloid leukemia
- targeted therapies
- mutations in AML
- treatment options
- oncology advancements
Keywords
- AML
- targeted therapy
- mutations
- oncology
- treatment advancements
Mentioned in this episode
Organizations: Harvard Medical School, Massachusetts General Hospital, Cedars-Sinai Cancer
More episodes of Oncology News Central Peer-Spectives
- New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target”
- Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic
- Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
- Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
- “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions
- “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC
Explore listener stats, chart rankings, contacts and more on the Oncology News Central Peer-Spectives podcast page.